Screening for type 2 diabetes

Podcast & Infographic

Click to listen to the podcast

Click to download the Infographic

Screening for type 2 diabetes

E-learning Modules

Launch: 15 July 2024


Delay in diagnosis of diabetes and pre-diabetes is a world-wide problem. A Thai outpatient study at a tertiary hospital found a delay in diabetes diagnosis (defined by Thai Clinical Practice Guidelines) in 96.9% of 260 study participants, and identified a particular problem in those with hypertension and those using non-cash insurance schemes. To try and identify those with diabetes or pre-diabetes as early as possible, guidelines published in 2022 jointly from the ADA and EASD suggest screening for type 2 diabetes should begin for all adults at age 35, and if the results are normal, testing should be repeated at a minimum of 3-year intervals. For those with risk factors including those with overweight or obesity, those with high-risk race/ethnicity, those physically inactive, those with hypertension, testing should begin at a younger age and occur at more frequent intervals. In children and adolescents who are overweight or have obesity, or who have risk factors for diabetes, testing should be considered after the onset of puberty. In Pakistan, the higher prevalence of type 2 diabetes among younger individuals has prompted National Clinical Guidelines to recommend screening for all individuals to start at age 30. The aim of screening asymptomatic adults for pre-diabetes and type 2 diabetes is to facilitate earlier detection, diagnosis, and treatment, with the ultimate goal of improving health outcomes by preventing the development of secondary complications, particularly blindness and kidney failure. However, there is uncertainty about the effects of screening for type 2 diabetes on all‐cause mortality and diabetes‐related mortality. There are also issues with take-up of screening – individuals from lower socio-economic groups in developed areas were less likely to take up screening for diabetes, despite the fact that these populations are likely to be at higher risk of non-communicable diseases. Education and community out-reach are important if screening is to achieve its potential. Research is needed to produce reliable and accurate biomarkers for diabetes and pre-diabetes that can be used in community screening anywhere in the world.  

Learning Objectives

After listening to this podcast, participants will be able to:

Target Audience

Clinicians involved in endocrinology, particularly diabetes, pre-diabetes, obesity management and general practice.


English with voice-over into Spanish and Chinese


Antonio Ceriello

Antonio Ceriello

IRCCS MultiMedica
Milan, Italy

Save the Date

· Martin O. Savage ·

Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996.  His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 60 countries and has published 482 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.

· Antonio Ceriello ·

Antonio Ceriello is currently an award-winning research consultant at Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy. He has  worked internationally  both clinically and in research. His research interests are centred around cardiovascular disease and diabetes. He was a consultant with the National Institute of Health (NIH), in the US from 2003–2005, and a member of the writing committee for the American Heart Association Guidelines on Acute Hyperglycemia and Acute Coronary Syndromes. He has been instrumental in both the development (2008) and the update (2011) of the International Diabetes Federation (IDF) Committee Guidelines for Management of Post-meal Glucose. Currently, he is the Chairman of the Diabetes and Cardiovascular Diseases Study Group of the European Association for the Study of Diabetes (EASD). Professor Ceriello has been involved with numerous guidelines including the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (2012), European Society of Cardiology (ESC) Guidelines on Diabetes, Pre-diabetes, and Cardiovascular Diseases developed in collaboration with the EASD (2013 and 2019), and the Continuous Glucose Monitoring Metrics for Clinical Trials International Consensus developed by the ADA, ADCES, EASD, ISPAD, JDS, JDRF and endorsed by the FDA and EMA (2022). He has been appointed by IDF as Co-Chairman for the development of the 2024 Guidelines for the Management of Type 2 Diabetes in Different Settings and as Chairman for the 2025 IDF Global Meeting.

Professor Ceriello has published over 600 original papers and several book chapters. His current h-index is 102 (SCOPUS). He served as Associate Editor of Diabetes Care (2003–2011) and Diabetic Medicine (2005–2016). Currently he is Editor-in-Chief of Diabetes Research and Clinical Practice, the official IDF journal and serves on the editorial board of Cardiovascular Diabetology.